Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPH vs ATX Reward Processing in Youth at SUD Risk
NCT03781765Phase 4Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jun 2019
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of methylphenidate, atomoxetine in attention deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), conduct disorder (CD), sponsored by Icahn School of Medicine at Mount Sinai. Started Jun 2019; status: recruiting.
02
Drugs
methylphenidateatomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)oppositional defiant disorder (ODD)conduct disorder (CD)
Beyond the preview
Go deeper on NCT03781765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781765.